retatrutide phase 2 obesity nejm 2023 jastreboff (Eli Lilly's triple GLP-1/GIP/Glucagon receptor agonist) just delivered the most impressive + osteoarthritis data we've ever seen in the 3 TRIUMPH-4 trial: Precision obesity medicine: A phenotype-guided

Adiponectin is associated with improvement of endothelial function after rosiglitazone treatment in non-diabetic individuals with metabolic syndrome

Choline supplementation modifies the effects of developmental alcohol exposure on immune responses in adult rats

The rise also comes ahead of the golden quarter, and may see shoppers weighing up their weight loss against seasonal spend

What this means for you You'll need prior authorization, which requires: BMI 30 (or 27 with comorbidities) 6 months documented lifestyle efforts Possible step therapy (trying other medications first) Bottom line: Focus on meeting PA requirements

Insert the needle at the appropriate angle